MA50914A - Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes - Google Patents

Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes

Info

Publication number
MA50914A
MA50914A MA050914A MA50914A MA50914A MA 50914 A MA50914 A MA 50914A MA 050914 A MA050914 A MA 050914A MA 50914 A MA50914 A MA 50914A MA 50914 A MA50914 A MA 50914A
Authority
MA
Morocco
Prior art keywords
drh12
coding sequences
viral vectors
treatment methods
vectors including
Prior art date
Application number
MA050914A
Other languages
English (en)
French (fr)
Inventor
Robin R Ali
Alexander J Smith
Debra A Thompson
Original Assignee
Univ Michigan Regents
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents, Ucl Business Ltd filed Critical Univ Michigan Regents
Publication of MA50914A publication Critical patent/MA50914A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01105—Retinol dehydrogenase (1.1.1.105)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050914A 2017-11-15 2018-11-15 Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes MA50914A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762586624P 2017-11-15 2017-11-15

Publications (1)

Publication Number Publication Date
MA50914A true MA50914A (fr) 2020-09-23

Family

ID=66431192

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050914A MA50914A (fr) 2017-11-15 2018-11-15 Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes

Country Status (27)

Country Link
US (2) US20190142909A1 (enExample)
EP (2) EP3710590B1 (enExample)
JP (2) JP2021502978A (enExample)
KR (1) KR102704296B1 (enExample)
CN (2) CN111886340A (enExample)
AU (1) AU2018367606B2 (enExample)
BR (1) BR112020009828A2 (enExample)
DK (1) DK3710590T3 (enExample)
EA (1) EA202091194A1 (enExample)
ES (1) ES2983990T3 (enExample)
FI (1) FI3710590T3 (enExample)
HR (1) HRP20241073T1 (enExample)
HU (1) HUE068393T2 (enExample)
IL (2) IL308645B1 (enExample)
LT (1) LT3710590T (enExample)
MA (1) MA50914A (enExample)
MX (1) MX2020005008A (enExample)
MY (1) MY204271A (enExample)
PH (1) PH12020551319A1 (enExample)
PL (1) PL3710590T3 (enExample)
PT (1) PT3710590T (enExample)
RS (1) RS65881B1 (enExample)
SG (1) SG11202004527YA (enExample)
SI (1) SI3710590T1 (enExample)
SM (1) SMT202400321T1 (enExample)
WO (1) WO2019099696A1 (enExample)
ZA (1) ZA202003416B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110191954B (zh) 2016-07-08 2024-05-14 宾夕法尼亚州大学信托人 用于治疗涉及rdh12的病症和疾病的方法和组合物
EP4329882A4 (en) * 2021-04-27 2025-02-26 The Trustees of Columbia University in the City of New York METHODS AND COMPOSITIONS FOR REGULATING CHOLESTEROL EFFLUX TO PREVENT, TREAT OR CURE MACULAR DEGENERATION
CN115725659A (zh) * 2022-04-01 2023-03-03 首都医科大学附属北京同仁医院 一种应用视网膜原位基因编辑制作非人灵长类动物先天性黑矇模型的方法
CN118453915A (zh) * 2024-04-29 2024-08-09 中国医学科学院北京协和医院 一种针对rdh12突变的基因治疗药物
CN119432856B (zh) * 2024-12-30 2025-08-12 云舟生物科技(广州)股份有限公司 核酸分子、病毒颗粒及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
AU2011242527B2 (en) * 2010-04-23 2016-05-19 University Of Florida Research Foundation, Inc. rAAV-guanylate cyclase compositions and methods for treating Leber's congenital amaurosis-1 (LCA1)
WO2012167109A2 (en) * 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
JP6199965B2 (ja) * 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
ES2987090T3 (es) * 2014-07-24 2024-11-13 Massachusetts Eye & Ear Infirmary Terapia génica con RPGR para retinitis pigmentosa
CA2979229A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
PT3289080T (pt) * 2015-04-30 2021-11-19 Univ Columbia Terapia genética para doenças autossómicas dominantes
CN110191954B (zh) * 2016-07-08 2024-05-14 宾夕法尼亚州大学信托人 用于治疗涉及rdh12的病症和疾病的方法和组合物

Also Published As

Publication number Publication date
JP7615238B2 (ja) 2025-01-16
EA202091194A1 (ru) 2020-08-14
LT3710590T (lt) 2024-09-25
EP3710590A1 (en) 2020-09-23
CN111886340A (zh) 2020-11-03
DK3710590T3 (da) 2024-08-12
SG11202004527YA (en) 2020-06-29
SMT202400321T1 (it) 2024-11-15
EP4364803A3 (en) 2024-06-05
JP2023133434A (ja) 2023-09-22
US20190142909A1 (en) 2019-05-16
WO2019099696A1 (en) 2019-05-23
US20230190884A1 (en) 2023-06-22
CN117752822A (zh) 2024-03-26
RS65881B1 (sr) 2024-09-30
PH12020551319A1 (en) 2021-09-01
AU2018367606B2 (en) 2024-08-29
IL308645B1 (en) 2025-09-01
SI3710590T1 (sl) 2024-10-30
PL3710590T3 (pl) 2024-10-21
PT3710590T (pt) 2024-08-09
EP3710590A4 (en) 2021-06-23
KR20200088385A (ko) 2020-07-22
IL274609A (en) 2020-06-30
ZA202003416B (en) 2024-10-30
MX2020005008A (es) 2020-11-06
CA3082586A1 (en) 2019-05-23
EP4364803A2 (en) 2024-05-08
ES2983990T3 (es) 2024-10-28
IL274609B2 (en) 2024-05-01
BR112020009828A2 (pt) 2020-11-17
EP3710590B1 (en) 2024-07-17
KR102704296B1 (ko) 2024-09-05
AU2018367606A1 (en) 2020-06-25
IL308645A (en) 2024-01-01
JP2021502978A (ja) 2021-02-04
FI3710590T3 (fi) 2024-08-06
HRP20241073T1 (hr) 2024-11-08
HUE068393T2 (hu) 2024-12-28
MY204271A (en) 2024-08-20
IL274609B1 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
MA49631A (fr) Méthodes de traitement de la fibrose kystique
MA54105A (fr) Méthodes de traitement de la fibrose kystique
EP3813808A4 (en) Methods of treating substance abuse
HUE071243T2 (hu) Mikro-disztrofin bejuttatása adeno-asszociált vírus vektorral izomdisztrófia kezelésére
EP3490582A4 (en) METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE
EP3710590A4 (en) VIRAL VECTORS WITH RDH12-ENCODING REGIONS AND METHODS FOR TREATING RETINARY ADYSTROPHIES
IL259877A (en) Adeno-type viral vectors used to treat spinal muscular atrophy
HUE054768T2 (hu) AAV vektorok retina és CNS génterápiára
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
EP3519058C0 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF HAIR
EP3891175A4 (en) MODIFIED PROTEINS AND RELATED TREATMENT METHODS
EP3448263A4 (en) Electrotherapeutic treatment
EP3697915A4 (en) ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION SPECIFIC TO MUSCLES TO TREAT MUSCLE DYSTROPHY
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
EP3618783A4 (en) DEVICES AND METHODS FOR TREATMENT OF EYELIDS
DK3393579T3 (da) Øjenbehandlingssystem
EP3630101A4 (en) METHODS OF TREATMENT OF FIBROTIC DISEASES
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
EP3634422A4 (en) Methods of treating leukodystrophies
EP3599983A4 (en) ENDOSCOPES AND TREATMENT PROCEDURES
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
TWI800561B (zh) 毛髮處理方法
EP3302695C0 (en) MUSCLE TREATMENT DEVICES
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
EP3578162A4 (en) HAIR TREATMENT METHOD